In this short interview, Rodica Bălaşa discusses how cerebrospinal fluid analysis in multiple sclerosis has evolved with the introduction of the kappa free light chain index.
Watch the interview
How have kappa free light chains improved cerebrospinal fluid evaluation in multiple sclerosis?
In the interview, Rodica Bălaşa explains how cerebrospinal fluid evaluation in multiple sclerosis has evolved from a labor-intensive, subjective process to a more practical, quantitative, and cost-effective approach using kappa free light chains.
Key points discussed include:
- The evolution from oligoclonal bands to kappa free light chains in CSF diagnostics
- Why kappa free light chains offer a more objective and quantitative assessment
- How this shift improves efficiency and reproducibility
- The continued role of CSF as a complementary tool when non-invasive methods are insufficient
Throughout the interview, the focus is on balancing technological advances with clinical judgment—using kappa free light chains as a supportive tool when CSF analysis is unavoidable, while still prioritizing non-invasive assessments whenever possible.
In your experience, how can clinicians balance cost, availability, and diagnostic yield when deciding to perform a CSF analysis?
* Please note that all the captions were generated automatically. If they do not appear, click on CC in the navigation.
Key messages from Rodica Bălaşa
Cerebrospinal fluid evaluation in multiple sclerosis has evolved toward a more objective and standardized approach. In this interview, Rodica Bălaşa explains how kappa free light chains provide a quantitative alternative to traditional oligoclonal band testing, improving reproducibility and practical implementation.
Despite this progress, CSF analysis remains a complementary investigation rather than a first-line test. It is used selectively when clinical and imaging findings do not provide sufficient certainty.
Overall, the discussion highlights a modern, stepwise diagnostic strategy, integrating quantitative biomarkers when needed while prioritizing non-invasive assessments whenever possible.
Curious to learn more about the expert behind this interview?
Visit Rodica Bălaşa’s full biography for more insights into her expertise.
Rodica Bălaşa
Professor of Neurology at the University of Medicine, Pharmacy, Sciences and Technology „George Emil Palade” of Targu Mures (UMFST), Romania
Head of the Neurology 1 Clinic, Emergency Clinical County Hospital of Mures, Romania
Main field of research interest is the diagnosis and management of multiple sclerosis, cerebrospinal fluid biomarkers, and neuroimaging.
Active contributor to the development of diagnostic criteria and innovative approaches in MS care.
Media
Details
We value your opinion.
